Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
| Revenue (TTM) | $1.65B |
| Gross Profit (TTM) | $937.07M |
| EBITDA | $316.92M |
| Operating Margin | 9.62% |
| Return on Equity | -0.70% |
| Return on Assets | 2.83% |
| Revenue/Share (TTM) | $21.41 |
| Book Value | $13.41 |
| Price-to-Book | 1.19 |
| Price-to-Sales (TTM) | 0.62 |
| EV/Revenue | 1.81 |
| EV/EBITDA | 12.16 |
| Quarterly Earnings Growth (YoY) | 0.40% |
| Quarterly Revenue Growth (YoY) | 0.80% |
| Shares Outstanding | $77.77M |
| Float | $58.61M |
| % Insiders | 14.39% |
| % Institutions | 98.42% |
Volatility is currently contracting
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Integra (IART) To Contact Him Directly To Discuss Their Options
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Integra securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to learn more about your rights.
SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating Integra LifeSciences Holdings Corporation (NASDAQ: IART) on behalf of investors who may have suffered losses. If you purchased Integra securities and suffered losses, please contact the firm to learn more about the investigation. There is no cost or obligation.
Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion.
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Integra sees steady Specialty Surgery demand and improving efficiency, but leverage and currency swings remain key challenges for Integra.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IART and any ticker you trade — then tracks every position and per-strategy win rate.
